Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug fabhalta under Real-World watch in korea for rare blood and kidney diseases

NCT ID NCT07416162

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is monitoring the safety and effectiveness of the drug iptacopan (Fabhalta) in 21 Korean adults with paroxysmal nocturnal hemoglobinuria (PNH) or C3 glomerulopathy (C3G). Researchers will track side effects and lab results from routine medical records. The goal is to see how well the drug works in everyday clinical practice, not in a controlled trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Iptacopan (Fabhalta)
What this could lead to
If successful, this study could confirm that iptacopan is safe and effective for managing PNH and C3G in real-world Korean patients.
What could go wrong
This is a small, observational post-marketing study with only 21 participants, so results may not apply broadly. It is designed to monitor safety, not to prove a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

complement 3 glomerulopathy Hemoglobinuria, Paroxysmal Hemolysis membranoproliferative glomerulonephritis paroxysmal nocturnal hemoglobinuria proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C3 GLOMERULOPATHY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Jeollanam, 519763, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 06591, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.